News Preview
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?
The article discusses Viking Therapeutics' oral obesity drug advancing to Phase 3 testing and explores whether it's a good time to invest in the biotech stock.
Want to stay up to date with the world events at sea or at home?
Explore Navvyx News - the best News app for seafarers.